3SBIO
3SBio is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people.
3SBIO
Social Links:
Industry:
Biotechnology
Founded:
1993-01-01
Address:
Shenyang, Liaoning, China
Country:
China
Website Url:
http://www.3sbio.com
Total Employee:
501+
Status:
Active
Contact:
+862425386000
Email Addresses:
[email protected]
Total Funding:
15 M CHF
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Apple Mobile Web Clips Icon Font Awesome Nginx Euro ASP.NET Apple Mobile Web App Capable IIS
Similar Organizations
HanBio Therapeutics
HanBio Therapeutics is a biotechnology company committed to researching and developing next generation transformative medicines.
Innovative Cellular Therapeutics
Innovative Cellular Therapeutics is a Shanghai-based biotechnology company engaged in research and development of cell therapy.
MabSpace Biosciences
MabSpace Biosciences is a biotech company focused on discovery & development of innovative antibody based therapeutics for cancer.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-09-03 | Therapure Biopharma | Therapure Biopharma acquired by 3sbio | 290 M USD |
| 2015-07-24 | Zhejiang Wansheng Pharmaceutical | Zhejiang Wansheng Pharmaceutical acquired by 3sbio | 85 M USD |
| 2015-01-26 | Sirton Pharmaceuticals | Sirton Pharmaceuticals acquired by 3sbio | N/A |
Investors List
Numab
Numab investment in Post-IPO Equity - 3sbio
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-12-20 | GenSight Biologics | 3sbio investment in Post-IPO Debt - GenSight Biologics | 15 M EUR |
| 2019-12-12 | Numab | 3sbio investment in Series B - Numab | 22 M CHF |
| 2019-10-21 | Verseau Therapeutics | 3sbio investment in Venture Round - Verseau Therapeutics | 50 M USD |
| 2018-05-02 | Refuge Biotechnologies | 3sbio investment in Series B - Refuge Biotechnologies | 25 M USD |
Official Site Inspections
http://www.3sbio.com Semrush global rank: 8.36 M Semrush visits lastest month: 320
- Host name: 123.56.139.115
- IP address: 123.56.139.115
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "3sbio"
3SBio Inc. - Crunchbase Company Profile & Funding
3SBio is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on …See details»
3SBio, Inc. - Drug pipelines, Patents, Clinical trials
May 7, 2025 Explore 3SBio, Inc. with its drug pipeline, therapeutic area, technology platform, 178 clinical trials, 34 news, and 26 literature, Disease …See details»
3SBio Inc Company Profile - 3SBio Inc Overview - GlobalData
3SBio Inc (3SBio) is a biotechnology company that discovers, develops, manufactures and markets biopharmaceutical products. The company develops recombinant or genetically …See details»
3SBio Inc. Company Profile | Kwun Tong, Hong Kong | Competitors ...
Find company research, competitor information, contact details & financial data for 3SBio Inc. of Kwun Tong. Get the latest business insights from Dun & Bradstreet.See details»
3Sbio - VentureRadar
3SBio (3S Pharmaceutical Group) is a leading bio-pharmaceutical company integrating R&D, production and sales, with a focus on improving the life quality of patients with high-quality …See details»
3sbio Company Profile - Office Locations, Competitors, Revenue
Oct 29, 2024 3sbio has 5 employees at their 1 location and ¥9.11 b in annual revenue in FY 2024. See insights on 3sbio including office locations, competitors, revenue, financials, …See details»
3SBio - 2025 Company Profile & Funding - Tracxn
May 21, 2025 3SBio develops, manufactures, markets, and sells biopharmaceuticals. Its products include TPIAO, a recombinant human thrombopoietin for thrombocytopenia; and …See details»
3SBio: Revenue, Worth, Valuation & Competitors 2025
3SBio has an estimated revenue of $71.6M, and 462 employees. Alternatives of 3SBio are Dermavant Sciences, Metrum Research Group and Clovis Oncology. ... Organization 3SBio …See details»
3SBIO - wshxl.com
3SBio is committed to shar pening its focus on refined management and ensuring the healthy developmen... 2023-03-21. 3SBio announces 2022 interim results, with net pro... with net profit …See details»
3SBio (FRA:83B) Company Profile & Description - Stock Analysis
3 days ago 3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides …See details»
Our core values - 3sbio.com
We have successfully achieved good results under the support of a comprehensive R & D platform. 3SBio relies on a professional R & D team composed of more than 300 scientists, …See details»
3SBio Inc.: history, ownership, mission, how it works & makes money
[relinking] Home History Owners Mission How It Works How It Makes Money A Brief History of 3SBio Inc. Founded in 1993, 3SBio Inc. is a biopharmaceutical company based in China, …See details»
Corporate Presentation - 3sbio.com
Tony He ([email protected]) Chief Financial Officer January 16th, 2025 ... (whether within or outside your organization/firm) or published or otherwise disclosed, in whole or in part, in any …See details»
3SBio Inc. - Contacts, Employees, Board Members, Advisors
Organization. 3SBio Inc. Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. Number of Board …See details»
3SBIO | OUR SCIENCE
3SBio always regards product quality as the lifeline of the enterprise. The Group has the National Engineering Research Center of Antibody Medicine approved by the National Development …See details»
3SBIO | NEWS CENTER
3SBio is committed to sharpening its focus on refined management and e... 2022-08-24 / News 3SBio announces 2022 interim results, with net profit attributable to owners of the parents …See details»
3SBIO
3SBio Unveils 2024 Interim Results: Reve... 2024-03-20 3SBio reveals 2023 annual results: Reven... More. Our 3SBio. Survey. Chronicle of events. Honors. Main visual. Cooperation …See details»
Pfizer Enters into Exclusive Licensing Agreement with 3SBio | Pfizer
May 19, 2025 Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese …See details»
Pfizer signs giant cancer drug deal with Chinese biotech - Axios
May 20, 2025 Pfizer on Tuesday announced a cancer drug licensing deal with Chinese biotech 3SBio that includes a $1.25 billion upfront payment and $4.8 billion in potential earnouts. …See details»
3SBio (HKG:1530) Company Profile & Description - Stock Analysis
3 days ago 3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides …See details»